Spero Therapeutics, Inc. (SPRO) Return on equity 2017–2025
Spero Therapeutics, Inc. (SPRO) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
14.5%FY2025 · since FY2017: -45.8% → 14.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 14.5% | +163.2 pp |
| FY2024 | -148.7% | -170.0 pp |
| FY2023 | 21.3% | +82.5 pp |
| FY2022 | -61.1% | +40.6 pp |
| FY2021 | -101.7% | -42.4 pp |
| FY2020 | -59.3% | +22.4 pp |
| FY2019 | -81.7% | -45.6 pp |
| FY2018 | -36.1% | +9.7 pp |
| FY2017 | -45.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice